Loading
Loading
Research Overview
Long R3 analogue of IGF-1 with reduced IGF-binding protein affinity, giving longer systemic half-life. Activates IGF-1R and downstream PI3K/Akt/mTOR and Ras/MAPK pathways to stimulate cell growth, proliferation, and protein synthesis.
IGF-1 LR3 is a modified form of IGF-1 in which an N-terminal extension and a single amino acid substitution dramatically reduce binding to the six IGF-binding proteins that normally regulate IGF-1 availability in biological systems. This reduced IGFBP binding results in a higher proportion of unbound, biologically active compound and an extended half-life compared to native IGF-1, making LR3 a useful research tool for studying IGF receptor signalling without the confounding effects of IGFBP-mediated sequestration.
In preclinical cell biology research, IGF-1 LR3 has been extensively used to study IGF-1 receptor (IGF-1R) signalling through the PI3K-Akt-mTOR and Ras-ERK pathways, which mediate cell survival, proliferation, and protein synthesis. Its extended activity window compared to native IGF-1 has made it a preferred research tool in cell culture systems where sustained IGF-1R stimulation is required for experimental paradigms.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, igf-1 lr3 (long arginine 3 igf-1) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
IGF-1 LR3 (Long Arginine 3 IGF-1) research is most relevant to protocols examining:
Systemic anabolic signalling and muscle protein synthesis research
PI3K/Akt/mTOR pathway investigation
GH-insensitivity and IGF-1 axis downstream research
Comparative studies with IGF-1 DES on half-life and binding protein effects
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~20–30 hours). Review data, confirm baseline recovery before any repeat protocol.
Long R3 analogue of IGF-1 with reduced IGF-binding protein affinity, giving longer systemic half-life. Activates IGF-1R and downstream PI3K/Akt/mTOR and Ras/MAPK pathways to stimulate cell growth, proliferation, and protein synthesis.
| Parameter | Value |
|---|---|
| Dose range | 20–60 mcg/day |
| Schedule | Daily |
| Route | Subcutaneous, Intramuscular |
| Half-life | ~20–30 hours |
particularly without carbohydrates proximate to dosing
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.